<DOC>
	<DOCNO>NCT00666718</DOCNO>
	<brief_summary>This study design look basal bolus regimen insulin lispro protamine suspension ( ILPS ) provide glycemic control basal bolus regimen insulin glargine ( one basal bolus regimen inject daily together insulin lispro inject 2-3 time daily ) .</brief_summary>
	<brief_title>A Comparison Study Basal Bolus Therapies Together With Lispro Insulin Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>Diabetes Mellitus , Type 2 Have receive metformin least one oral antihyperglycemic medication ( sulfonylurea thiazolidinedione ) insulin least 3 month prior Visit 1 ( Screening ) Hemoglobin A1C ( HbA1c ) great equal 7.5 % less equal 11.0 % Body Mass Index ( BMI ) great equal 25 less equal 45 kg/m^2 Capable willing follow protocol Give write consent Are take glucoselowering agent ( list inclusion criterion ) Have history severe hypoglycemia past 6 month Are pregnant may become pregnant Women breastfeed Have significant cardiac disease Have significant renal liver disease Undergoing therapy malignancy Contraindications study medication Have irregular sleep/wake cycle Have serious disease condition consider investigator exclusionary</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>